MA
NKTR icon

Montag & Associates’s Nektar Therapeutics NKTR Stock Holding History

Montag & Associates’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18K Buy
+250
New +$14.2K ﹤0.01% 691
2025
Q4 		– Sell
-7
Closed -$399 – 1094
2025
Q3 		$399 Buy
+7
New +$232 ﹤0.01% 1096

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Montag & Associates's NKTR Position: Q1 2026 in Review

Montag & Associates opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 250 shares worth $18K. The stake represents ﹤0.01% of the portfolio and ranks #691 among its holdings. This is a return to the name: Montag & Associates previously reported a position in NKTR as recently as Q3 2025.

Montag & Associates first reported a position in NKTR in Q3 2025 and has held it in 2 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Montag & Associates held 250 shares of Nektar Therapeutics worth $18K as of Q1 2026.
  • Nektar Therapeutics was a new Montag & Associates position in Q1 2026.
  • Nektar Therapeutics made up ﹤0.01% of Montag & Associates's portfolio in Q1 2026, its #691 holding.
  • Montag & Associates first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Montag & Associates's 13F filing for Q1 2026, filed 29 Apr 2026.